Expanded genetic testing can match cancer patients with personalized treatment options that standard screenings often miss, a new study said.
This finding suggests that broader tumor DNA sequencing can uncover actionable targets, potentially expanding the range of available therapies for patients who have exhausted standard care options.
Researchers at the London Health Sciences Centre Research Institute (LHSCRI) conducted the study in London, Ontario. The team sought to determine if broader sequencing could identify specific genetic markers that make a patient eligible for targeted drugs or clinical trials.
The results indicate that approximately one-third of cancer participants were identified as eligible for additional therapies based on this expanded genetic testing [1]. This represents a significant portion of the patient group who might otherwise have remained on less effective, general treatments.
Standard genetic tests often look for a limited set of known mutations. The LHSCRI approach uses more comprehensive sequencing to scan for a wider array of genetic alterations within the tumor DNA. By mapping these mutations, clinicians can better align a patient's specific biological profile with existing medical treatments.
The study was released this month and highlights a shift toward precision medicine. By identifying these targets, the research aims to move cancer care away from a one-size-fits-all model, and toward a strategy based on the individual genetic makeup of the tumor.
“Expanded genetic testing can match cancer patients with personalized treatment options.”
The shift toward expanded genomic profiling suggests that a significant percentage of cancer patients may be underserved by current standard-of-care diagnostic protocols. If broader sequencing becomes a clinical norm, it could increase the rate of successful targeted therapy matches, reducing the reliance on broad-spectrum chemotherapy and improving patient outcomes through precision medicine.
